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Background: Stroke is a leading cause of death worldwide. Infections after stroke occur in 30% of stroke patients
and are strongly associated with unfavourable outcome. Preventive antibiotic therapy lowers infection rate in patients
after stroke, however, the effect of preventive antibiotic treatment on functional outcome after stroke has not yet been
investigated.The Preventive Antibiotics in Stroke Study (PASS) is an ongoing, multicentre, prospective, randomised,
open-label, blinded end point trial of preventive antibiotic therapy in acute stroke. Patients are randomly assigned
to either ceftriaxone at a dose of 2 g, given every 24 hours intravenously for four-days, in addition to stroke-unit care,
or standard stroke-unit care without preventive antibiotic therapy. Aim of the study is to assess whether preventive
antibiotic treatment improves functional outcome at three months by preventing infections.
Results: To date, 2,470 patients have been included in PASS. Median stroke severity of the first 2,133 patients (second
interim analysis) is 5 (IQR 3 to 9) on the National Institutes of Health Stroke Scale (NIHSS). Due to the PROBE design,
no outcome data are available yet. In the initial trial protocol we proposed a dichotomisation of the mRS as primary
analysis of outcome and ordinal regression analysis as secondary analysis of primary outcome, requiring a sample size
of 3,200 patients. However, ordinal analysis of outcome data is becoming increasingly more common in acute stroke
trials, as it increases statistical power. For PASS, funding is insufficient for inclusion of 3,200 patients with the overall
inclusion rate of 15 patients per week. Therefore we change the analysis of our primary outcome from dichotomisation
to ordinal regression analysis on the mRS. Power analysis showed that with similar assumptions 2,550 patients are
needed using ordinal regression analysis. We expect to complete follow-up in June 2014. A full statistical analysis plan
will be submitted for publication before treatment allocation will be unblinded.
Conclusion: The data from PASS will establish whether preventive antibiotic therapy in acute stroke improves
functional outcome by preventing infection. In this update, we changed our primary outcome analysis from
dichotomisation to ordinal regression analysis.
Trial registration: Current controlled trials; ISRCTN66140176. Date of registration: 6 April 2010.
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Preventive Antibiotics in Stroke Study (PASS)
Stroke is a leading cause of death worldwide. Infections
after stroke occur in 30% of stroke patients and are strongly
associated with unfavourable outcome [1,2]. Preventive
antibiotic therapy lowers infection rate in patients after
stroke; however, the effect of preventive antibiotic treat-
ment on functional outcome after stroke has not yet been
investigated [3,4].
The aim of PASS is to investigate whether preventive
use of the antibiotic ceftriaxone improves functional
outcome in patients with stroke. PASS is an ongoing,
multicentre Prospective, Randomised, Open-label, Blinded
End point trial (PROBE) of standard care with preventive
ceftriaxone treatment which is compared with standard
care without preventive ceftriaxone. Adult patients with
stroke (both ischaemic and haemorrhagic) and a score ≥ 1
on the National Institutes of Health Stroke Scale will
be included. Patients are randomly assigned to either
ceftriaxone at a dose of 2 g, given every 24 hours
intravenously for four-days, in addition to stroke-unit
care, or standard stroke-unit care without preventive
antibiotic therapy. All items from the World Health
Organization Trial Registration Data Set are shown in
Table 1. For description of the entire study protocol,
including study procedures and data collection, assessment
of infections and outcomes, allocation and blinding proce-
dures, we refer to the initial trial protocol publication
[5]. Changes to the protocol since the first version are
shown in Table 2. Medical-ethical approval of the protocol
and amendments was obtained by the medical ethical
committee of the AMC. All participating centres are
shown in Table 3.
The primary end point of the PASS is functional out-
come at three-month follow-up on the modified Rankin
Scale (mRS), a well-validated functional outcome scale
in stroke patients [6]. In the protocol publication, the
primary efficacy end point has been defined as the
functional outcome at the three-month follow-up, as
assessed by the mRS dichotomised as a favourable out-
come (mRS 0 to 2) or as an unfavourable outcome
(mRS 3 to 6). The proportional odds model was de-
fined as the secondary analysis of the primary end
point [5]. Secondary outcome measures were death
rate at discharge and three-months, infection rate dur-
ing hospital admission, length of hospital admission,
volume of post-stroke care, use of antibiotics during
follow-up, Quality-adjusted life years (QALYs); and
costs. In this update publication of PASS, we change
our primary outcome analysis from dichotomisation
to ordinal regression analysis on the mRS. We also
change the secondary outcome of use of antibiotics
during follow-up into use of antibiotics during hos-
pital stay.Change in primary analysis of primary outcome and
adaptation of sample size
The modified Rankin Scale is a well-validated functional
scale for assessing outcome after stroke. Analysis on a
dichotomisation in favourable versus unfavourable out-
come delivers easily comprehensible results. However,
cut-off is arbitrarily and solely based on improvement
beyond this one cut-off point. A secondary analysis
including 55 datasets of stroke trials showed that statis-
tical analysis based on the ordered nature of functional
outcome data versus dichotomisation was more efficient
and more likely to deliver reliable results [7]. Although
there were some annotations regarding this publication,
more and more studies are using ordinal regression ana-
lysis [8-10].
In the design of PASS, both dichotomisation and ordinal
regression analysis were described as analysis of the
primary outcome [5]. We based our initial sample size
calculation on the dichotomised outcome (favourable
versus unfavourable outcome). Dichotomisation was
chosen as primary analysis of efficacy because of the
widespread use in stroke trials [5,11]. However, trial
completion will take an unrealistically long time with
excessive costs with the current inclusion rate of 15
patients per week. Therefore, we now propose a switch
in primary analysis of the primary outcome using an
ordinal outcome analysis. The primary outcome will
remain to be assessed on the mRS. The primary outcome
with dichotomisation will be presented as secondary
analysis of primary outcome. Using ordinal regression
analysis for PASS enables us to preserve the assumptions
of the strength of the treatment effect with a lower total
sample size.
Sample size
We based our initial sample size calculation on the dichoto-
mised outcome (favourable versus unfavourable outcome).
With the assumption of reduction of unfavourable outcome
of 5%, with a power of 80% and P-value of 0.05, we aimed
to include 3,200 patients.
We now propose a new sample size of 2,550 patients,
which is based on the ordinal regression analysis of the
primary outcome. For this analysis we will use the ‘pro-
portional odds model’, also known as the ‘cumulative
logit model’ [12]. The assumption for the distribution on
mRS in the control-arm is based on the control-arm in
the Paracetamol (Acetaminophen) In Stroke (PAIS) trial,
which had almost similar inclusion criteria as PASS [13].
We assumed a proportional odds ratio of 0.818 between
all pairs of category groups, similar to the assumption in
the original sample size calculation (odds ratio of 0.818
for mRS 0 to 2 versus mRS 3 to 6). Figure 1 shows the
expected distribution of the two treatment arms. Using
the method of Whitehead, with alpha 0.05 and power
Table 2 Protocol revision chronology
Date Protocol version and amendments
5 May 2010 Original protocol
15 August 2010 Protocol version 1.1. Amendments: exclusion criterion ‘death seems imminent’ added; compulsory urine analysis and
culture on admission omitted.
9 December 2010 Protocol version 1.2. Amendments: new study centres with new estimations of included patients were added; paragraph 6.6
‘drug-accountability’: badge number of the administered ceftriaxone will be noted by the nurse administrating the medication
into the ‘drug accountability form’ according to GCP-guidelines for pharmacies; paragraph 7.2 ‘randomisation, blinding and
treatment allocation’: randomisation will not be stratified according to stroke type, solely by study centre and stroke severity;
assessment of blinded outcome is specified as performed by a person not involved in the trial team; performance of interim
analyses is specified as performed by an independent statistician not involved in the trial team; paragraph 8.2 ‘adverse and
serious adverse events’: for each participating centre, a flowchart of serious adverse event/suspected unexpected serious
adverse reactions (SAE/SUSAR) reporting will be provided in the local Investigator File; paragraph 8.5 ‘data monitoring’:
reference to the monitoring plan is added.
10 January 2014 Protocol version 1.3. Amendment: change in primary analysis of primary outcome from dichotomised analysis to ordinal
regression analysis according to the proportional odds model.
Total course of study Participating centres were added (all participating centres are shown in Table 3).
Table 1 All items from the World Health Organization Trial Registration Data Set (SPIRIT checklist, item 2b)
Data category Information
Primary registry and trial
identifying number
Current controlled trials; www.controlled-trials.com; ISRCTN66140176
Date of registration in
primary registry
6 April 2010
Secondary identifying numbers -
Source(s) of monetary or
material support
1. Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)
(ref: 171002302) 2. Netherlands Heart Foundation (Nederlandse Hartstichting) (Netherlands) (ref: CD 300006)
Primary sponsor Academic Medical Centre (AMC) (Netherlands)
Secondary sponsor(s) -
Contact for public queries Paul J Nederkoorn; P.J.Nederkoorn@amc.uva.nl
Contact for scientific queries Paul J Nederkoorn, Department of Neurology, Academic Medical Centre, PO box 22660, 1100 DD Amsterdam,
The Netherlands.
Public title Preventive Antibiotics in Stroke Study
Scientific title Preventive ceftriaxone to improve functional health in patients with stroke by preventing infection:
a multicentre prospective randomised controlled trial
Countries of recruitment The Netherlands
Health condition(s) or
problem(s) studied
Stroke, infection
Intervention(s) Optimal medical care and ceftriaxone 2,000 mg intravenously, once daily, for four days, versus optimal
medical care without ceftriaxone.
Key inclusion and exclusion criteria Inclusion criteria: aged greater than or equal to 18 years, either sex; stroke (ischaemic and haemorrhagic);
any measurable neurological deficit defined as National Institutes of Health Stroke Scale (NIHSS) greater than 1;
stroke onset less than 24 hours; admission.
Exclusion criteria: symptoms or signs of infection on admission requiring antibiotic therapy; use of antibiotics
less than 24 hours before admission; pregnancy; hypersensitivity for cephalosporin; previous anaphylaxis for
penicillin or derivates; subarachnoid haemorrhage; death seems imminent.
Study type Multicentre prospective randomised open-label blinded end point trial
Date of first enrolment 4 July 2010
Target sample size 2,550
Recruitment status Recruiting
Primary outcome(s) Functional health at three-month follow-up, as assessed by the modified Rankin Scale (mRS)
Key secondary outcomes Death rate at discharge and three months, infection rate during hospital admission; length of hospital admission;
volume of post-stroke care; use of antibiotics during hospital stay; Quality adjusted life years (QALYs); costs.
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Table 3 Centres participating in the Preventive Antibiotics
in Stroke Study (PASS) with local investigators
Centre Local investigator
Academic Medical Centre, Amsterdam PJ Nederkoorn; D van de Beek
Albert Schweitzer Hospital, Dordrecht H Kerkhoff
Amphia Hospital, Breda MJM Remmers
Amstelland Hospital, Amstelveen DSM Molenaar
Atrium Medical Centre, Heerlen T Schreuder
Boven-IJ Hospital, Amsterdam M Janmaat
Bronovo Hospital, The Hague SM Manschot
Catharina Hospital, Eindhoven K Keizer
Erasmus Medical Centre, Rotterdam DWJ Dippel
Groene Hart Hospital, Gouda K de Gans
HAGA Hospital, The Hague SF de Bruijn
Kennemer Gasthuis, Haarlem M Weisfelt
Laurentius Hospital, Roermond ML van Goor
Martini Hospital, Groningen ES Schut
Medical Centre Haaglanden, The Hague K Jellema
Medical Centre Alkmaar R ten Houten
Onze Lieve Vrouwe
Gasthuis Amsterdam
JLM Bosboom
Orbis Medical Centre, Sittard N van Orshoven
Rijnstate Hospital, Arnhem SE Vermeer
Reinier de Graaf Hospital, Delft LAM Aerden
Slotervaart Hospital, Amsterdam ND Kruyt
Spaarne Hospital, Hoofddorp ISJ Merkies
St. Franciscus Gasthuis, Rotterdam FH Vermeij
University Medical Centre
Radboud, Nijmegen
E van Dijk
University Medical Centre, Utrecht HB van der Worp
VU Medical Centre, Amsterdam MC Visser
Westfries Gasthuis Hoorn TC van der Ree
Ijsselland Hospital, Capelle aan den IJssel AD Wijnhoud
Zaans Medical Centre, Zaandam RM van den Berg - Vos
ZGT, Almelo LJA Reichman
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model is estimated at a total of 2,410 patients [14]. Given
an expected rate of patients lost to follow-up and/or
patients with incomplete data of 5%, a conservative
estimate for the new sample size with the primary end
point analysed on all categories of the mRS is 2,531
patients. We will therefore adapt the sample size to 2,550
patients; a reduction of 650 patients compared to the
original sample size estimate based on a dichotomous
outcome on the mRS. This decision has been made by
the researchers without any knowledge of outcome data
per treatment group.Recruitment target
By 12 February 2014, 2,470 patients were included in
the PASS. Up-to-date statistics can be found at www.
passamc.nl. With a stable weekly inclusion rate of 15
patients, follow-up of the last included patient is expected
in June 2014.
Definitions of infection
Infection rate during hospital admission will be assessed
in two ways. First, clinical diagnosis according to the
treating physician will be recorded. Second, diagnosis of
infection will be judged by two experienced infectious
diseases specialists, blinded for treatment allocation,
using the modified criteria of the United States Centres
for Disease Control and Prevention [15]. This will be
done in all patients who developed fever or a new onset
delirium during admission, in patients in whom there was
suspicion of infection but no diagnostics were performed,
and in patients in a palliative care setting. One important
issue that needs to be addressed is the risk of performance
and detection bias. Since the treating physician is aware
of the treatment allocation, this could influence decisions
on non-scheduled treatment. For the PASS, the most
important issue to address is the detection and treatment
of infection. A physician could be more or less likely
to order investigations or start treatment for a possible
infection depending on the treatment allocation. By giving
recommendations for diagnostic procedures in the previ-
ously mentioned subgroups of patients, and by collecting
results of these procedures in standardized case record
forms, we try to limit this form of bias.
Monitoring of antibiotic resistance
One of the most important mechanisms of resistance
against third generation cephalosporins is forming of
extended-spectrum-β-lactamase (ESBL), an enzyme that
renders antibiotics ineffective, in Enterobacteriaceae. In
our study we monitor the prevalence of ESBL-producing
bacteria in both treatment arms. We therefore collect
stool specimens at admission and discharge in a subgroup
of patients. To date, samples have been obtained in 300
patients.
Development of the statistical analysis plan
Currently, the statistical analysis plan is being finalised,
without insight in to the unblinded data. It will be pub-
lished before the randomisation code is broken in late
2014. The statistical analysis plan describes the analysis
of primary outcome with ordinal regression analysis
and a secondary dichotomised analysis into detail. It
also describes a small number of prespecified subgroup
analyses, and a larger number of exploratory secondary
analyses, that will be performed, as well as treatment of
missing values.
modified Rankin Scale
17%
14%
26%
24%
11%
11%
15%
15%
9%
10%
7%
8%
15%
18%
Intervention
Control
mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5 mRS 6
Figure 1 Expected distribution of the two treatment arms. The assumption for the distribution on mRS in the control-arm is based on the
control-arm in the Paracetamol (Acetaminophen) In Stroke (PAIS) trial, which had almost similar inclusion criteria as PASS [9].
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The PASS aims to investigate whether preventive anti-
biotic therapy improves functional outcome by prevent-
ing infections. The results of a trial examining the effect
of preventive antibiotic therapy on functional outcome
are urgently warranted. Infection after stroke is common
and infection has repeatedly been shown to worsen out-
come [1,2,16,17]. Since previous studies on preventive
antibiotic therapy were too small, heterogeneous, or did
not investigate functional outcome, no sufficient informa-
tion is available on the role of preventive antibiotic therapy
in acute stroke [4].
With this update of the protocol, we present a change
in primary analysis of the primary outcome on the mRS
from a dichotomised analysis to an ordinal regression
analysis. Ordinal analysis of outcome data is increasingly
common in acute stroke trials as well as in other trials, for
example on traumatic brain injury [7,18]. Data is used more
efficiently with ordinal analysis as compared to a dichoto-
mised analysis. For example the ECASS-II trial failed to
show an effect of treatment in the dichotomised approach,
but did show an affect with ordinal shift analysis [19].
Different approaches can be used for the analysis of
ordinal outcome data. In the PASS we chose the ordinal
regression analysis as primary analysis of outcome, which
was already described as a secondary analysis of primary
outcome in the original protocol. The proportional odds
model provides additional information from ordinal out-
come data, as it takes into account improvements at any
point on the mRS [18]. This method is highly efficient
when compared to a dichotomised approach, but also when
compared to other ordinal approaches [18]. A possible
disadvantage of this approach is the assumption of pro-
portional odds across all groups. In PASS, we chose this
method because we expected a similar effect of preventive
antibiotic treatment across all outcomes, and thereforeexpect to meet the assumptions of the proportional odds
model.
With the new sample size of 2,550 patients we expect
completion of inclusion of patients in PASS in June 2014.
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